| Literature DB >> 20378655 |
William R Schwan1, Adam Briska2, Buffy Stahl2, Trevor K Wagner2, Emily Zentz2, John Henkhaus2, Steven D Lovrich3, William A Agger3, Steven M Callister3, Brian DuChateau4, Colin W Dykes2.
Abstract
Optical maps were generated for 33 uropathogenic Escherichia coli (UPEC) isolates. For individual genomes, the NcoI restriction fragments aligned into a unique chromosome map for each individual isolate, which was then compared with the in silico restriction maps of all of the sequenced E. coli and Shigella strains. All of the UPEC isolates clustered separately from the Shigella strains as well as the laboratory and enterohaemorrhagic E. coli strains. Moreover, the individual strains appeared to cluster into distinct subgroups based on the dendrogram analyses. Phylogenetic grouping of these 33 strains showed that 32/33 were the B2 subgroup and 1/33 was subgroup A. To further characterize the similarities and differences among the 33 isolates, pathogenicity island (PAI), haemolysin and virulence gene comparisons were performed. A strong correlation was observed between individual subgroups and virulence factor genes as well as haemolysis activity. Furthermore, there was considerable conservation of sequenced-strain PAIs in the specific subgroups. Strains with different antibiotic-resistance patterns also appeared to sort into separate subgroups. Thus, the optical maps distinguished the UPEC strains from other E. coli strains and further subdivided the strains into distinct subgroups. This optical mapping procedure holds promise as an alternative way to subgroup all E. coli strains, including those involved in infections outside of the intestinal tract and epidemic strains with distinct patterns of antibiotic resistance.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20378655 PMCID: PMC3068680 DOI: 10.1099/mic.0.033977-0
Source DB: PubMed Journal: Microbiology (Reading) ISSN: 1350-0872 Impact factor: 2.777
Bacterial strains used in this study
| GLMC 9 | Gundersen Lutheran Medical Center |
| GLMC 10 | Gundersen Lutheran Medical Center |
| GLMC 15 | Gundersen Lutheran Medical Center |
| GLMC 21 | Gundersen Lutheran Medical Center |
| GLMC 100 | Gundersen Lutheran Medical Center |
| GLMC 101 | Gundersen Lutheran Medical Center |
| GLMC 103 | Gundersen Lutheran Medical Center |
| GLMC 106 | Gundersen Lutheran Medical Center |
| GLMC 503 | Gundersen Lutheran Medical Center |
| GLMC 505 | Gundersen Lutheran Medical Center |
| GLMC 506 | Gundersen Lutheran Medical Center |
| GLMC 508 | Gundersen Lutheran Medical Center |
| GLMC 509 | Gundersen Lutheran Medical Center |
| GLMC 513 | Gundersen Lutheran Medical Center |
| GLMC 514 | Gundersen Lutheran Medical Center |
| GLMC 515 | Gundersen Lutheran Medical Center |
| CV1117292 | Converge |
| CV1117298 | Converge |
| CV1117326 | Converge |
| CV1117621 | Converge |
| CV1118322 | Converge |
| CV1118891 | Converge |
| CV1119429 | Converge |
| CV1119511 | Converge |
| CV1119857 | Converge |
| CV1121147 | Converge |
| CV1123039 | Converge |
| CV1125109 | Converge |
| CV1131494 | Converge |
| ATCC 25922 | ATCC |
| ATCC 8739 | ATCC |
| W3110 (K-12) | University of Wisconsin-La Crosse collection |
| DH10B (K-12) | |
| UTI89 | Scott Hultgren ( |
| CFT073 | Rod Welch ( |
| 536 | Jörg Hacker ( |
| NU14 | |
| NU149 | |
| APEC 01 | |
| Sakai | |
| EDL933 | |
| EC4115 | GenBank |
| E24377A | |
| SMS-3-5 | |
| HS | |
| SE11 | |
| CDC 3083-94 | GenBank |
| Sb227 | |
| Sd197 | |
| 2457T | |
| 301 | |
| 8401 | |
| Ss046 |
Fig. 1.Genome similarity clustering using UPGMA for the 33 UPEC isolates and the in silico maps of sequenced E. coli and Shigella strains.
Fig. 2.(a) Overview of optical maps of E. coli strains from the CFT073 subgroup. Comparison of optical maps with the in silico map of CFT073. The alignment software highlights restriction fragment differences shown in white between isolates, whereas homologous regions are highlighted in blue. (b) A closer look at three strains (UTI89, CFT073, NU14), with sequence alignments overlaid on top of the maps. The vertical lines represent matching NcoI restriction sites. Green rectangles represent some of the PAIs. The insert shows the PAI-CFT073-serX in strain CFT073 that is absent in both the UTI89 and the NU14 strains.
Fig. 3.Genome similarity clustering using UPGMA for E. coli isolates found in subgroups one and two, as well as phylogenetic grouping and haemolysis patterns.
Virulence factor gene distribution among uropathogenic E. coli isolates
+, Present; −, absent.
| GLMC 515 | + | – | + | + | + | + | + | – | + |
| CV1117326 | + | – | + | + | + | + | + | – | + |
| CFT073 | – | + | – | + | + | + | + | + | + |
| GLMC 9 | – | + | – | – | + | + | + | + | + |
| ATCC 25922 | – | + | – | + | + | + | + | + | + |
| NU149 | – | – | – | – | – | + | + | + | + |
| GLMC 505 | + | – | + | + | + | + | + | – | + |
| CV1123039 | + | – | – | + | + | + | + | – | + |
| UTI89 | + | – | + | + | + | + | + | – | + |
| NU14 | + | – | – | + | + | + | + | – | + |
| GLMC 15 | – | + | – | – | – | + | + | – | + |
| CV1118891 | – | + | – | – | + | + | + | – | + |
| CV1119511 | – | + | – | – | – | + | + | – | + |
| GLMC 506 | – | + | – | – | – | + | + | – | + |
| GLMC 513 | – | – | – | – | + | + | + | – | + |
| GLMC 509 | + | + | – | + | + | + | + | – | + |
| CV1125109 | + | + | + | + | + | + | + | – | + |
| GLMC 503 | + | – | + | + | + | + | + | – | + |
| CV1117621 | + | – | + | + | + | + | + | – | + |
| GLMC 514 | + | – | + | + | + | + | + | – | + |
| GLMC 103 | + | – | + | + | – | + | + | + | + |
| 536 | – | – | + | + | + | + | + | – | + |
| CV1121147 | – | – | – | – | + | + | + | – | + |
| CV1117292 | – | – | – | – | – | + | + | – | + |
| GLMC 101 | – | + | – | + | – | + | + | + | + |
| GLMC 106 | – | – | – | – | – | + | + | + | + |
| CV1119429 | – | – | – | – | – | + | – | + | + |
| GLMC 100 | – | – | – | – | – | + | + | + | + |
| CV1131494 | – | – | – | – | – | + | + | + | + |
| CV1118322 | – | – | – | – | – | + | + | + | + |
| CV1117298 | – | – | – | – | – | + | + | + | + |
| GLMC 508 | – | – | – | – | – | + | – | + | + |
| CV1119857 | – | – | – | – | – | + | + | + | + |
| GLMC 10 | – | – | – | – | – | + | + | + | + |
| GLMC 21 | – | – | – | – | – | + | + | – | – |
| W3110 (K-12) | – | – | – | – | – | + | + | – | – |
Antibacterial drug susceptibilities of 30 recent uropathogenic E. coli isolates and ATCC strain 25922
| GLMC 515 | S† | S | S | S | S | S | S | S | S | S | – | S | S | – | S |
| CV1117326 | S | S | S | S | S | S | S | S | S | S | S | ||||
| GLMC 9 | S | S | S | S | S | S | S | – | S | – | – | S | |||
| ATCC 25922 | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| GLMC 505 | S | S | S | S | S | S | S | S | S | S | – | S | S | – | S |
| CV1123039 | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| GLMC 15 | S | S | S | S | S | S | S | – | S | S | – | S | |||
| CV1118891 | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| CV1119511 | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| GLMC 506 | S | S | S | S | S | S | S | S | – | S | S | – | S | ||
| GLMC 513 | S | S | S | S | S | S | S | S | S | S | – | S | S | – | S |
| GLMC 509 | S | S | S | S | S | S | S | – | S | S | – | S | |||
| CV1125109 | S | S | S | S | S | S | S | S | S | S | S | ||||
| GLMC 503 | S | S | S | S | S | S | S | S | S | S | – | S | S | – | S |
| CV1117621 | S | S | S | S | S | S | S | S | S | S | S | S | S | S | |
| GLMC 514 | S | S | S | S | S | S | S | S | S | S | – | S | S | – | S |
| GLMC 103 | S | S | S | S | S | S | S | S | S | S | – | S | – | S | |
| CV1121147 | S | S | S | S | S | S | S | S | S | S | S | S | S | ||
| CV1117292 | S | S | S | S | S | S | S | S | S | S | S | S | |||
| GLMC 101 | S | S | S | S | S | S | S | S | – | S | S | – | S | ||
| GLMC 106 | S | S | S | S | S | S | S | – | S | S | – | S | |||
| CV1119429 | S | S | S | S | S | S | S | S | S | S | S | S | S | ||
| GLMC 100 | S | S | S | S | S | S | S | S | – | S | S | – | S | ||
| CV1131494 | S | S | S | S | S | S | S | S | S | ||||||
| CV1118322 | S | S | S | S | S | S | S | S | S | ||||||
| CV1117298 | S | S | S | S | S | S | S | S | S | ||||||
| GLMC 508 | S | S | S | S | S | – | S | – | S | ||||||
| CV1119857 | S | S | S | S | S | S | S | S | S | ||||||
| GLMC 10 | S | S | S | S | S | S | S | S | – | S | – | S | |||
| GLMC 21 | S | S | S | S | S | S | S | – | S | S | – | S | |||
*The following antibacterial drugs were used: AM, ampicillin; SAM, ampicillin/sulbactam; PIP, piperacillin; TZP, piperacillin/tazobactam; CZ, cefazolin; CTT, cefotetan; CRO, ceftriaxone; FEP, cefepime; MEM, meropenem; CIP, ciprofloxacin; LVX, levofloxacin; SXT, trimethoprim/sulfa; F/M, nitrofurantoin; NN, tobramycin; GM, gentamicin.
†S, Susceptible; I, intermediate; R, resistant; –, not determined.